Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study

Background— Fetuin-A is a multifunctional hepatic secretory protein that inhibits the action of insulin in experimental animals. We evaluated the association between human serum fetuin-A and the metabolic syndrome (MetS) in a cohort of persons with coronary artery disease. Methods and Results— We defined MetS by the National Cholesterol Education Program criteria among 711 nondiabetic outpatients with coronary artery disease. The mean age was 67 years, and 82% were male. We divided participants into quartiles by serum fetuin-A concentrations. A total of 45% of participants (80 of 177) in the highest quartile of fetuin-A had MetS compared with 24% of participants (42 of 177) in the lowest quartile (odds ratio, 2.7; 95% confidence interval, 1.7 to 4.2; P<0.001). This association persisted after adjustment for potential confounding variables, including hypertension, body mass index, and inflammatory biomarkers (adjusted odds ratio, 2.0; 95% confidence interval, 1.1 to 3.5; P=0.02). Higher fetuin-A quartiles were also strongly and independently associated with higher low-density lipoprotein, non–high-density lipoprotein (HDL), and triglyceride concentrations and lower HDL concentrations (all P<0.01). Conclusions— Higher human fetuin-A concentrations are strongly associated with MetS and an atherogenic lipid profile. Future studies should evaluate whether fetuin-A predicts coronary artery disease risk.

[1]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[2]  P. Deedwania.  Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? , 2003, Circulation.

[3]  M. Shlipak,et al.  Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. , 2003, Journal of the American Society of Nephrology : JASN.

[4]  J. Rumsfeld,et al.  Depressive symptoms and health-related quality of life: the Heart and Soul Study. , 2003, JAMA.

[5]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[6]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[7]  W. Browner,et al.  C-Reactive Protein and Ischemia in Users and Nonusers of &bgr;-Blockers and Statins: Data From the Heart and Soul Study , 2003, Circulation.

[8]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[9]  Ronald Klein,et al.  Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. , 2002, Diabetes care.

[10]  G. Grunberger,et al.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. , 2002, Diabetes.

[11]  Will F. Figueira,et al.  Discovery of a High Molecular Weight Complex of Calcium, Phosphate, Fetuin, and Matrix γ-Carboxyglutamic Acid Protein in the Serum of Etidronate-treated Rats* , 2002, The Journal of Biological Chemistry.

[12]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[13]  G. Grunberger,et al.  Insulin Signaling : From Cultured Cells to Animal Models , 2002 .

[14]  J. Beckman,et al.  Relationship of Clinical Presentation and Calcification of Culprit Coronary Artery Stenoses , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Ridker,et al.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. , 2001, Circulation.

[16]  Roger D. Kamm,et al.  The Impact of Calcification on the Biomechanical Stability of Atherosclerotic Plaques , 2001, Circulation.

[17]  J. Weber,et al.  Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Dina,et al.  Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. , 2000, American journal of human genetics.

[19]  F. Sablitzky,et al.  Cloning and Targeted Deletion of the Mouse Fetuin Gene* , 1997, The Journal of Biological Chemistry.

[20]  G. Grunberger,et al.  Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. , 1997, Life sciences.

[21]  W. Jahnen-Dechent,et al.  The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. , 1996, The Journal of biological chemistry.

[22]  G. Grunberger,et al.  Baculoviral expression of a natural inhibitor of the human insulin receptor tyrosine kinase. , 1995, Biochemical and biophysical research communications.

[23]  G. Grunberger,et al.  Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. , 1993, Molecular endocrinology.

[24]  R. Kamm,et al.  Distribution of Circumferential Stress in Ruptured and Stable Atherosclerotic Lesions A Structural Analysis With Histopathological Correlation , 1993, Circulation.

[25]  M. Haasemann,et al.  The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. , 1992, European journal of biochemistry.

[26]  M. Haasemann,et al.  Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2-HS glycoprotein and bovine fetuin. , 1991, The Biochemical journal.

[27]  S. Eisenberg,et al.  Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. , 1991, The Journal of clinical investigation.

[28]  M. Jensen,et al.  Insulin Regulation of Lipolysis in Nondiabetic and IDDM Subjects , 1989, Diabetes.

[29]  G. Pagès,et al.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity , 1989, Cell.

[30]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[31]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[32]  J. Raoult,et al.  Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. , 1979, The Journal of clinical investigation.

[33]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[34]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[35]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[36]  J. Lebreton,et al.  Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  P. Arnaud,et al.  Human Recombinant Alpha2-HS Glycoprotein is Produced in Insect Cells as a Full Length Inhibitor of the Insulin Receptor Tyrosine Kinase , 1998 .

[38]  G. Lewis,et al.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. , 1995, The Journal of clinical investigation.

[39]  D. Cockroft.  Comparison of in vitro and in vivo development of rat foetuses. , 1976, Developmental biology.

[40]  A. Clauss.  [Rapid physiological coagulation method in determination of fibrinogen]. , 1957, Acta haematologica.